References

ateroskleroz

Атеросклероз

Ateroscleroz

2078-256X2949-3633

НИИТПМ-филиал ИЦиГ СО РАН

ateroskleroz-725

Research Article

ОРИГИНАЛЬНЫЕ СТАТЬИ

ORIGINAL ARTICLES

Вклад генов Toll-подобных рецепторов в этиопатогенез ишемической болезни сердца

The contribution of Toll-like receptor genes in the etiopathogenesis of coronary artery disease

Ипатова

В. А.

Ipatova

V. A.

Вера Андреевна Ипатова, младший научный сотрудник

СО РАМН

ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний»

отдел экспериментальной и клинической кардиологии

лаборатория геномной медицины

650002

Сосновый бульвар, 6

Кемерово

SB RAMS

Research Institute for Complex Issues of Cardiovascular Diseases

650002

Sosnovy Blvd., 6

Kemerovo

ipatva@kemcardio.ru

Понасенко

А. В.

Ponasenko

A. V.

Анастасия Валерьевна Понасенко, зав. лабораторией

отдел экспериментальной и клинической кардиологии

лаборатория геномной медицины

СО РАМН

ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний»

650002

Сосновый бульвар, 6

Кемерово

SB RAMS

Research Institute for Complex Issues of Cardiovascular Diseases

650002

Sosnovy Blvd., 6

Kemerovo

ponaav@kemcardio.ru

Хуторная

М. В.

Khutornaya

M. V.

Мария Владимировна Хуторная, младший научный сотрудник

СО РАМН

ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний»

отдел экспериментальной и клинической кардиологии

лаборатория геномной медицины

650002

Сосновый бульвар, 6

Кемерово

SB RAMS

Research Institute for Complex Issues of Cardiovascular Diseases

650002

Sosnovy Blvd., 6

Kemerovo

masha_hut@mail.ru

Цепокина

А. В.

Tsepokina

A. V.

Анна Викторовна Цепокина, младший научный сотрудник

СО РАМН

ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний»

отдел экспериментальной и клинической кардиологии

лаборатории геномной медицины

650002

Сосновый бульвар, 6

Кемерово

SB RAMS

Research Institute for Complex Issues of Cardiovascular Diseases

650002

Sosnovy Blvd., 6

Kemerovo

annacepokina@mail.ru

Головкин

А. С.

Golovkin

A. S.

Алексей Сергеевич Головкин, д-р мед. наук, зав. отделом

СО РАМН

ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний»

отдел экспериментальной и клинической кардиологии

650002

Сосновый бульвар, 6

Кемерово

SB RAMS

Research Institute for Complex Issues of Cardiovascular Diseases

650002

Sosnovy Blvd., 6

Kemerovo

goloas@kemcardio.ru

РАМНRAMS

2014

14042022

1041018

2022

Ипатова В.А., Понасенко А.В., Хуторная М.В., Цепокина А.В., Головкин А.С.

Ipatova V.A., Ponasenko A.V., Khutornaya M.V., Tsepokina A.V., Golovkin A.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://ateroskleroz.elpub.ru/jour/article/view/725

Настоящая работа направлена на обобщение имеющихся в настоящее время публикаций по проблеме вклада полиморфизмов генов рецепторов врожденного иммунитета, в частности Toll-like рецепторов, в патогенез атеросклеротического поражения сосудов сердца. Описаны сигнальные пути TLRs, а также многообразие имеющихся аллельных вариантов кодирующих их генов и взаимосвязь полиморфных вариантов TLRs с различными патологическими состояниями. Показана достоверная связь отдельных аллельных вариантов генов TLRs с развитием и прогрессированием атеросклероза в различных популяциях. Исследования в этой области весьма ограничены и требуют дополнительного изучения.

The article presents a review of current meta-analyses on innate immune receptor gene polymorphisms, such as Toll-like receptors, and their potential role in the pathogenesis of coronary atherosclerotic lesions. TLR signaling pathways, as well as available allelic variations of genes encoding them, and the relationship between TLR polymorphic variants with different pathological conditions have been described. The article reveals significant associations of individual TLR gene alleles with the development and progression of atherosclerosis in different populations. However, the research in this area is rather limited and requires further study.

атеросклерозгеныполиморфизмыаллельные вариантыToll-like рецепторы

atherosclerosisgenespolymorphismsallelic variantsToll-like receptors

References1

Статинова Е. А. Инфекционные агенты в развитии атеросклероза / Е. А. Статинова, Р. Я. Омельченко, А. О. Аурсалиди // Атеросклероз. – 2013. – № 4. – С. 51–64.

Hasan U. A., Trinchieri G., Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts // J. Biol. Chem. 2005. Vol. 280, N 21. P. 20620–20627.

Chen G. Y., Nuñez G. Review. Sterile inflammation: sensing and reacting to damage // Nat. Rev. Immunol. 2010. Vol. 10, N 12. P. 826–837.

Тухватуллин А. И. Toll-подобные рецепторы и их адапторные молекулы / А. И. Тухватуллин, Д. Ю. Логунов, Д. Н. Щербинин // Биохимия. – 2010. – Т. 75, № 9. – С. 1224–1243.

Wan Y., Xiao H., Affolter J. et al. Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control // J. Biol. Chem. 2009. Vol. 284, N 16. P. 10367–10375.

Basith S., Manavalan B., Lee G. et al. Toll-like receptor modulators: a patent review // Expert. Opin. Ther. Pat. 2011. Vol. 21, N 6. P. 927–944.

McGettrick A. F., O’Neill L. A. Localisation and trafficking of Toll-like receptors: an important mode of regulation // Curr. Opin. Immunol. 2010. Vol. 22, N 1. P. 20–27.

Barton G. M., Medzhitov R. Toll-like receptor signaling pathways // Science. 2003. Vol. 300. P. 1524–1525.

Engel A. L., Holt G. E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system // Expert. Rev. Clin. Pharmacol. 2011. Vol. 4, N 2. P. 275–289.

Liu Y., Chen H., Sun Y., Chen F. Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection // Mol. Biol. Rep. 2012. Vol. 39, N 2. P. 1163–1172.

Huang L. Y., Dumontelle J. L., Zolodz M. et al. Use of toll-like receptor assays to detect and identify microbial contaminants in biological products // J. Clin. Microbiol. 2009. Vol. 47, N 11. P. 3427–3434.

Mashima R., Saeki K., Yoshimura A. et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling // J. Biol. Chem. 2005. Vol. 280, N 50. P. 41289–41297.

Jain S., Chodisetti S. B., Agrewala J. N. et al. CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B cells // PloS ONE. 2011. Vol. 6, N 6. P. e20651.

Wang Y., Lehner T. Induction of innate immunity in control of mucosal transmission of HIV // Curr. Opin. HIV AIDS. 2011. Vol. 6, N 5. P. 398–404.

Salem M. L., El-Naggar S. A., Cole D. J. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo // Cell Immunol. 2010. Vol. 261, N 2. P. 134–143.

Asprodites N., Zheng L., Geng D. et al. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity // FASEB J. 2008. Vol. 22, N 10. P. 3628–3637.

Lin Q., Li M., Fang D. et al. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases // Int. Immunopharm. 2011. Vol. 11, N 10. P. 1422–1432.

Crellin N. K., Garcia R. V., Hadisfar O. et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells // J. Immunol. 2005. Vol. 175, N 12. P. 8051–8059.

Sutmuller R. P., Morgan M. E., Netea M. G. et al. Toll-like receptors on regulatory T cells: expanding immune regulation // Trends. Immunol. 2006. Vol. 27, N 8. P. 387–393.

Jung Y. O., Cho M. L., Lee S.Y. et al. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice // Immunol. Lett. 2009. Vol. 123, N 2. P. 138–143.

Lu Q., Darveau R. P., Samaranayake L. P. et al. Differential modulation of human {beta}-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures // Innate Immun. 2009. Vol. 15, N 6. P. 325–335.

Aoki M. P., Carrera-Silva E. A., Cuervo H. et al. Non-immune cells contribute to crosstalk between immune cells and inflammatory mediators in the innate response to Trypanosoma cruzi infection // J. Parasitol. Res. 2012. Vol. 10. P. 13.

Arumugam T. V., Okun E., Tang S. et al. Toll-like receptors in ischemia-reperfusion injury // Shock. 2009. Vol. 32, N 1. P. 4–16.

Хаитов Р. М., Пащенко М. В., Пинегин Б. В. Роль паттернраспознающих рецепторов во врожденном и адаптивном иммунитете / Р. М. Хаитов, М. В. Пащенко, Б. В. Пинегин // Иммунология. – 2009. – № 1. – С. 66–76.

Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart // Am. J. Physiol. Heart. Circ. Physiol. 2009. Vol. 296. P. H1–H12.

Boyd J. H., Mathur S., Wang Y., Bateman R. M., Walley K. R. Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappa B dependent inflammatory response // Cardiovasc. Res. 2006. Vol. 72. P. 384–393.

Nemoto S., Vallejo J. G., Knuefermann P. at al. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart // Am. J. Physiol. Heart Circ. Physiol. 2002. Vol. 282. P. H2316–H2323.

Knuefermann P., Sakata Y., Baker J. S. at al. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart // Circulation. 2004. Vol. 110. P. 3693–3698.

Zhu X., Bagchi A., Zhao H. at al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction // Crit. Care Med. 2007. Vol. 35, N 3. P. 886–892.

Hansson G. K., Libby P., Schonbeck U. et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis // Circ. Res. 2002. Vol. 91. P. 281–291.

Ohashi K., Burkart V., Flohe S. et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex // J. Immunol. 2000. Vol. 164. P. 558–561.

Vabulas R. M., Ahmad-Nejad P., da Costa C. et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells // J. Biol. Chem. 2001. Vol. 276. P. 31332–31339.

Edfeldt K., Swedenborg J., Hansson G. K. et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation // Circulation. 2002. Vol. 105. P. 1158–1161.

Xu X. H., Shah P. K., Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL // Circulation. 2001. Vol. 104. P. 3103–3108.

Лиходед В. Г. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза / В. Г. Лиходед, В. М. Бондаренко, А. Л. Гинцбург // Рос. кардиол. журн. – 2010. – Т. 82, № 2. – С. 92–96.

Ashida K., Miyazaki K., Takayama E. at al. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease // J. Atheroscler. Thromb. 2005. Vol. 12. P. 53–60.

Versteeg D., Hoefer I. E., Schoneveld A. H. et al. Monocyte Toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve // Heart. 2008. Vol. 94. P. 770 –776.

Rittersma S. Z. H., Hovinga J. A. K., Koch K. T. et al. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and Toll-Receptor 4 gene polymorphisms // Clin. Chem. 2005. Vol. 51, N 3. P. 516–521.

Mullick A. E., Soldau K., Kiosses W. B. et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events // J. Exp. Med. 2008. Vol. 205. P. 373–383.

Brunn G. J., Bungum M. K., Johnson G. B., Platt J. L. Conditional signaling by Toll-like receptor 4 // FASEB J. 2005. Vol. 19. P. 872–874.

Rifkin I. R., Leadbetter E. A., Busconi L. at al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease // Immunol. Rev. 2005. Vol. 204. P. 27–42.

Ishikawa Y., Satoh M., Itoh T. et al. Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction // Clin. Sci. (Lond). 2008. Vol. 115. P. 133–140.

Methe H., Kim J. O., Kofler S. et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 1439–1445.

Tavener S. A., Long E. M., Robbins S. M. et al. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia // Circ. Res. 2004. Vol. 95. P. 700–707.

Bjorkbacka H., Kunjathoor V.V., Moore K.J. et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways // Nat. Med. 2004. Vol. 10. P. 416–421.

O’Neill L. A., Bowie A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling // Nat. Rev. Immunol. 2007. Vol. 7. P. 353–364.

Monaco C., Gregan S. M., Navin T. J. et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human // Circulation. 2009. Vol. 120. P. 2462–2469.

Misch E. A., Hawn T. R. Toll-like receptor polymorphisms and susceptibility to human disease // Clin. Sci. 2008. Vol. 114. P. 347–360.

Ferwerda B., McCall M. B., Alonso S. et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans // Proc. Nat. Acad. Sci. 2007. Vol. 104. P. 16645–16650.

Schmitt C., Humeny A., Becker C. M. et al. Polymorphisms of TLR4: Rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles // Clin. Chem. 2002. Vol. 48. P. 1661–1667.

Ioana M., Ferwerda B., Plantinga T. S. et al. Different patterns of Toll-like receptor 2 polymorphisms in populations of various ethnic and geographic origins // Infect. Immun. 2012. Vol. 80, N 5. P. 1917–1922.

Lorenz E., Mira J. P., Cornish K. L. et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection // Infect. Immun. 2000. Vol. 68. P. 6398–6401.

Texereau J., Chiche J., Taylor W. et al. The importance of Toll-Like receptor 2 polymorphisms in severe infections // Clin. Infect. Dis. 2005. Vol. 41. P. 408–415.

Скочко О. В. Значение полиморфизма Asp299Gly Toll-подобного рецептора 4 в патогенезе атеросклероза / О. В. Скочко // Актуальні проблеми сучасної медицини. – 2013. – Т. 2, № 42. – С. 229–232.

Hamann L., Gomma A., Schroder N. W. et al. A frequent Toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis // J. Mol. Med. 2005. Vol. 83. P. 478–485.

Labrum R., Bevan S., Sitzer M. et al. Toll Receptor polymorphisms and carotid artery intima-media thickness // Stroke. 2007. Vol. 38. P. 1179–1184.

Arbour N. C., Lorenz E., Schutte B. C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans // Nat. Genet. 2000. Vol. 25. P. 187–191.

Kiechl S., Lorenz E., Reindl M. et al. Toll-like receptor 4 polymorphisms and atherogenesis // N. Engl. J. Med. 2002. Vol. 347. P. 185–192.

Ameziane N., Beillat T., Verpillat P. et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. e61–e64.

Boekholdt S. M., Agema W. R., Peters R. J. et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events // Circulation. 2003. Vol. 107. P. 2416–2421.

Yang I. A., Holloway J. W., Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis // Atherosclerosis. 2003. Vol. 170. P. 187–190.

Von Aulock S., Schroder N. W., Gueinzius K. et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood // J. Infect. Dis. 2003. Vol. 188. P. 938–943.

Erridge C., Stewart J., Poxton I. R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signaling // J. Exp. Med. 2003. Vol. 197. P. 1787–1791.

Edfeldt K., Bennet A. M., Eriksson P. et al. Association of hyporesponsive toll-like receptor 4 variants with risk of myocardial infarction // Eur. Heart J. 2004. Vol. 25. P. 1447–1453.

Kuivenhoven J. A., Jukema J. W., Zwinderman A. H. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis // N. Engl. J. Med. 1998. Vol. 338. P. 86–93.

Radstake T. R., Franke B., Hanssen S. et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome // Arthr. Rheum. 2004. Vol. 50. P. 999–1001.

Menghini R., Campia U., Tesauro M. et al. Toll-like receptor 4 mediates endothelial cell activation through NF-kB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis // PLoS ONE. 2014. Vol. 9, N 6. P. e99053.

Netea M. G., Hijmans A., van Wissen S. et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia // Eur. J. Clin. Invest. 2004. Vol. 34. P. 94–99.

Zhang K., Zhang L., Zhou B. et al. Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis // Thromb. Res. 2012. Vol. 130. P. e203–e208.

Koch W., Hoppmann P., Pfeufer A. et al. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population // Eur. Heart J. 2006. Vol. 27. P. 2524–2529.

The authors declare that there are no conflicts of interest present.